PT3423060T - Imatinib para utilização no tratamento de acidente vascular cerebral - Google Patents

Imatinib para utilização no tratamento de acidente vascular cerebral

Info

Publication number
PT3423060T
PT3423060T PT177603990T PT17760399T PT3423060T PT 3423060 T PT3423060 T PT 3423060T PT 177603990 T PT177603990 T PT 177603990T PT 17760399 T PT17760399 T PT 17760399T PT 3423060 T PT3423060 T PT 3423060T
Authority
PT
Portugal
Prior art keywords
imatinib
stroke
treatment
Prior art date
Application number
PT177603990T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hamra Invest Ab
Brain Consultant Nils Gunnar Wahlgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamra Invest Ab, Brain Consultant Nils Gunnar Wahlgren Ab filed Critical Hamra Invest Ab
Publication of PT3423060T publication Critical patent/PT3423060T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT177603990T 2016-02-29 2017-02-27 Imatinib para utilização no tratamento de acidente vascular cerebral PT3423060T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke

Publications (1)

Publication Number Publication Date
PT3423060T true PT3423060T (pt) 2021-10-20

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177603990T PT3423060T (pt) 2016-02-29 2017-02-27 Imatinib para utilização no tratamento de acidente vascular cerebral

Country Status (17)

Country Link
US (2) US10953010B2 (enExample)
EP (1) EP3423060B1 (enExample)
JP (1) JP6914957B2 (enExample)
CN (2) CN119523986A (enExample)
AU (1) AU2017227515B2 (enExample)
DK (1) DK3423060T3 (enExample)
ES (1) ES2895432T3 (enExample)
HR (1) HRP20211621T1 (enExample)
HU (1) HUE056798T2 (enExample)
LT (1) LT3423060T (enExample)
PL (1) PL3423060T3 (enExample)
PT (1) PT3423060T (enExample)
RS (1) RS62465B1 (enExample)
RU (1) RU2739382C1 (enExample)
SE (1) SE539450C2 (enExample)
SI (1) SI3423060T1 (enExample)
WO (1) WO2017151043A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
AU2007240429A1 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Ltd Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.

Also Published As

Publication number Publication date
HUE056798T2 (hu) 2022-03-28
EP3423060A4 (en) 2020-01-01
HRP20211621T1 (hr) 2022-02-04
PL3423060T3 (pl) 2022-01-10
JP2019507165A (ja) 2019-03-14
US10953010B2 (en) 2021-03-23
SE1650260A1 (en) 2017-08-30
US20190030030A1 (en) 2019-01-31
US20210236488A1 (en) 2021-08-05
AU2017227515B2 (en) 2022-03-24
LT3423060T (lt) 2021-11-10
CN108697711A (zh) 2018-10-23
SI3423060T1 (sl) 2021-11-30
JP6914957B2 (ja) 2021-08-04
CN119523986A (zh) 2025-02-28
WO2017151043A1 (en) 2017-09-08
RU2739382C1 (ru) 2020-12-23
DK3423060T3 (da) 2021-10-25
ES2895432T3 (es) 2022-02-21
SE539450C2 (en) 2017-09-26
AU2017227515A1 (en) 2018-08-30
EP3423060A1 (en) 2019-01-09
EP3423060B1 (en) 2021-07-21
RS62465B1 (sr) 2021-11-30

Similar Documents

Publication Publication Date Title
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
GB201608885D0 (en) Treatment
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL251904B (en) Epilimod for use in the treatment of melanoma
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
HUE054065T2 (hu) Szerek glióma kezelésében történõ alkalmazásra
GB201608797D0 (en) Therapeutic use
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
PT3423060T (pt) Imatinib para utilização no tratamento de acidente vascular cerebral
IL272658A (en) surface treatment
GB201418809D0 (en) Therapeutic agents and uses thereof
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
SI3303486T1 (sl) Sestavek za površinsko obdelavo
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB201508831D0 (en) Improvements in upper body clothing
GB2551906B (en) Body component
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
TWM534166U (en) Can body
GB201511772D0 (en) Improvements in the treatment of ash